NEW YORK (GenomeWeb) – Immunexpress said today it has received 510(k) clearance from the US Food and Drug Administration for the use of its Septicyte Lab, an RNA-based blood test that helps clinicians determine whether an infection has caused a patient's systemic inflammation.

Immunexpress noted that being able to rapidly differentiate infection-positive systemic inflammation, or sepsis, from infection-negative systemic inflammation, or systemic inflammatory response syndrome (SIRS), can save lives and reduce healthcare costs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.